← FDA DRUG APPROVALS

FDA ANDA · ANDA078862

HIVES RELIEF

cetirizine tablets

Sponsor: ORBION PHARMS

APPLICATION
ANDA078862
TYPE
ANDA
ORIGINAL APPROVAL
2009-02-19
LATEST ACTION
2014-11-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Over-the-counter

Products

CETIRIZINE HYDROCHLORIDE HIVESOver-the-counter
CETIRIZINE HYDROCHLORIDE 10MG · TABLET · ORAL
CETIRIZINE HYDROCHLORIDE ALLERGYOver-the-counter
CETIRIZINE HYDROCHLORIDE 10MG · TABLET · ORAL
CETIRIZINE HYDROCHLORIDE HIVESOver-the-counter
CETIRIZINE HYDROCHLORIDE 5MG · TABLET · ORAL
CETIRIZINE HYDROCHLORIDE ALLERGYOver-the-counter
CETIRIZINE HYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2014-11-07Manufacturing (CMC) · Supplement 2AP
2014-11-05Labeling · Supplement 3 · standardAP
2009-02-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →